Hoppa till sidans huvudinnehåll
Pharmaceutical companies, academic researchers, and government agencies such as the Food and Drug Administration and the National Institutes of Health all possess large quantities of clinical research data. If these data were shared more widely within and across sectors, the resulting research advances derived from data pooling and analysis could improve public health, enhance patient safety, and spur drug development. Data sharing can also increase public trust in clinical trials and conclusions derived from them by lending transparency to the clinical research process. Much of this information, however, is never shared. Retention of clinical research data by investigators and within organizations may represent lost opportunities in biomedical research. Despite the potential benefits that could be accrued from pooling and analysis of shared data, barriers to data sharing faced by researchers in industry include concerns about data mining, erroneous secondary analyses of data, and unwarranted litigation, as well as a desire to protect confidential commercial information.Academic partners face significant cultural barriers to sharing data and participating in longer term collaborative efforts that stem from a desire to protect intellectual autonomy and a career advancement system built on priority of publication and citation requirements. Some barriers, like the need to protect patient privacy, pre- sent challenges for both sectors. Looking ahead, there are also a number of technical challenges to be faced in analyzing potentially large and heterogeneous datasets. This public workshop focused on strategies to facilitate sharing of clinical research data in order to advance scientific knowledge and public health. While the workshop focused on sharing of data from preplanned interventional studies of human subjects, models and projects involving sharing of other clinical data types were considered to the extent that they provided lessons learned and best practices. The workshop objectives were to examine the benefits of sharing of clinical research data from all sectors and among these sectors, including, for example: benefits to the research and development enterprise and benefits to the analysis of safety and efficacy.Sharing Clinical Research Data: Workshop Summary identifies barriers and challenges to sharing clinical research data, explores strategies to address these barriers and challenges, including identifying priority actions and "low-hanging fruit" opportunities, and discusses strategies for using these potentially large datasets to facilitate scientific and public health advances.

Produktinformation

  • Utgivningsdatum2013-05-07
  • Mått152 x 229 x 13 mm
  • Vikt340 g
  • FormatHäftad
  • SpråkEngelska
  • SerieClinical Trial Data Sharing
  • Antal sidor156
  • FörlagNational Academies Press
  • ISBN9780309268745

Tillhör följande kategorier

Hoppa över listan

Mer från samma författare

To Err Is Human

Institute of Medicine, Committee on Quality of Health Care in America, Molla S. Donaldson, Janet M. Corrigan, Linda T. Kohn

Häftad

869 kr

From Neurons to Neighborhoods

National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson

Häftad

499 kr

Bereavement

Institute of Medicine, Committee for the Study of Health Consequences of the Stress of Bereavement

Häftad

1 259 kr

New Vaccine Development

Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health

Häftad

1 019 kr

Physician Staffing for the VA

Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb

Häftad

629 kr

Hoppa över listan

Mer från samma serie

Challenges for the FDA

Institute of Medicine, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development

Häftad

679 kr

Breakthrough Business Models

Institute of Medicine, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development, Robert Giffin, Sally Robinson, Theresa Wizemann

Häftad

769 kr

Hoppa över listan

Du kanske också är intresserad av

Deriving Drug Discovery Value from Large-Scale Genetic Bioresources

and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development, Roundtable on Genomics and Precision Health, Sarah H. Beachy, Steve Olson, Amanda Wagner Gee, Siobhan Addie

Häftad

709 kr

Sharing Clinical Trial Data

Institute of Medicine, Board on Health Sciences Policy, Committee on Strategies for Responsible Sharing of Clinical Trial Data

Häftad

1 019 kr

Ovarian Cancers

and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Health Care Services, Committee on the State of the Science in Ovarian Cancer Research

Häftad

1 179 kr

Biomarker Tests for Molecularly Targeted Therapies

and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Health Care Services, Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies, Harold L. Moses, Jonathan K. Phillips, Laurene A. Graig

Häftad

969 kr

Challenges for the FDA

Institute of Medicine, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development

Häftad

679 kr